Vectalys and FlashCell merge into Flash Therapeutics, loaded with RNA pipeline and manufacturing set-up
Two gene therapy companies in France are merging to create one venture called Flash Therapeutics, combining manufacturing know-how with a pipeline of RNA drug prospects.
The merger is between Vectalys, a Toulouse-based maker of lentiviral vectors, and its spinout startup FlashCell, which launched out of Vectalys just last year to tackle RNA carriers for drug applications.
The CEO of the combined company, Pascale Bouillé, tells me the merger partly came down to biomanufacturing industrial logic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.